SCHEMBL2874248

SCHEMBL2874248

[CH2]CC(=O)N(C)CC(C)(C)NC(=O)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.46
CTSS P25774 3/20 0.44
CTSL P07711 2/20 0.44
CTSB P07858 2/20 0.44
CTSK P43235 2/20 0.44
LMNA P02545 3/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ALDH1A1 P00352 2/20 0.41
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40
KCNA5 P22460 1/20 0.40
SYK P43405 1/20 0.40
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16207904 0.89 SMN1; SMN2 (0.47) MEN1KMT2ASMN1; SMN2CTSSCTSL
SCHEMBL2188090 0.84 SMN1; SMN2 (0.52) MEN1KMT2ASMN1; SMN2CTSSCTSL
SCHEMBL2870482 0.82 PTPN2 (0.43) MEN1KMT2ASMN1; SMN2CTSSCTSL
SCHEMBL12975087 0.82 MEN1 (0.41) MEN1KMT2ASMN1; SMN2CTSSCTSL
SCHEMBL2187660 0.81 MEN1 (0.55) MEN1KMT2ASMN1; SMN2CTSSCTSL
SCHEMBL848606 0.79 SMN1; SMN2 (0.50) MEN1KMT2ASMN1; SMN2CTSSCTSL
SCHEMBL567578 0.77 MEN1 (0.56) MEN1KMT2ASMN1; SMN2CTSSLMNA
SCHEMBL8282485 0.77 MEN1 (0.58) MEN1KMT2ASMN1; SMN2CTSSLMNA
SCHEMBL2187728 0.77 SMN1; SMN2 (0.45) MEN1KMT2ASMN1; SMN2CTSSCTSL
SCHEMBL4454463 0.77 SMN1; SMN2 (0.45) MEN1KMT2ASMN1; SMN2CTSSCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120965-B1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES NOVABAY PHARMACEUTICALS INC (US) 2014-11-05 EP disclosed
US-8415497-B2 N-halogenated amino compounds and derivatives NOVABAY PHARMACEUTICALS, INC. (US) 2013-04-09 US disclosed
US-20100311791-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES NOVABAY PHARMACEUTICALS, INC. 2010-12-09 US disclosed
EP-2120965-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES Novabay Pharmaceuticals, Inc. (US) 2009-11-25 EP disclosed
WO-2008083347-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES NOVABAY PHARMACEUTICALS, INC. (US) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311791-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES DCTD, DDC, DAO MEN1 2339/4885KMT2A 1714/4885SMN1; SMN2 4442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.